Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia
Novadip is developing NVD003, an autologous therapy derived from adipose stem cells, as a potential single treatment to save limbs and restore mobility in patients with CPT The RMAT designation is part of the IND that Novadip obtained for NVD003, with plans to reach the US market in 2027 Mont Saint-Guibert, Belgium, June @@, 2025 […]
Read Post
Tubulis Achieves Key Milestone in BMS Strategic License Agreement as First Collaboration Tubutecan ADC Enters the Clinic
The program, licensed exclusively to BMS, represents the third ADC candidate using the company’s proprietary Tubutecan technology to reach the clinic. MUNICH, GERMANY, May 20, 2025 – Tubulis today announced that the first program from its strategic license agreement with Bristol Myers Squibb has entered clinical development, triggering a significant milestone in the ongoing collaboration to develop next generation […]
Read Post
Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb
No refractures were reported during long-term follow-up at five years At 24-months post-implantation, 89% of patients achieved bone union Novadip plans market launch of NVD003 in 2027 Mont Saint-Guibert, Belgium, April 29, 2025 – Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces the five-year follow-up results from the Phase 1/2 […]
Read Post
Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion
Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogeneic product, in spine fusion NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) model In phase 1b/2a clinical trial, early bone fusion was observed at 12 months, coupled with no NVDX3-related […]
Read Post
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy
Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett syndrome (TREE study) Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study […]
Read Post
ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types • Dr. Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board • Dr. Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer • Accelerating […]
Read Post
Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached or are steadily progressing towards complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique “Off the Shelf” allogeneic matrix product to cure common but challenging orthopedic conditions, has the potential to replace existing allogeneic bone substitutes […]
Read Post
Confo Therapeutics Announces EUR 60M Series B Financing to Advance Pipeline of Novel GPCR-Modulating Therapies into Clinical Development
• Proceeds to support Phase 1 clinical trials for two proprietary programs, and to advance two additional programs to IND approval • Company to expand R&D efforts to discover additional development candidates for rare endocrine diseases and obesity, including those targeting Class B GPCRs • Portfolio expansion to include a focus on agonistic GPCR antibodies […]
Read Post
Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma
TUB-040 is a next-generation NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary P5 technology with superior biophysical properties that demonstrated effective and durable responses in a range of preclinical models The clinical trial will enroll up to 140 patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory adenocarcinoma non-small cell lung cancer in the US, the UK […]
Read Post
Novo Nordisk to acquire Cardior Pharmaceuticals and strengthen pipeline in cardiovascular disease
Bagsværd, Denmark, and Hannover, Germany, 25 March, 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to 1.025 billion Euros, including an upfront payment and additional payments if certain development and commercial milestones are achieved. Cardior is a leader in the discovery and development of […]
Read Post
Fund+ Portfolio Company Tubulis Closes Upsized EUR 128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
Financing round co-led by EQT Life Sciences and Nextech Invest1, with participation from current and new leading global biotechnology investors Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US MUNICH, GERMANY, March 14, 2024 – Tubulis, a Fund+ portfolio company, today […]
Read Post
Confo Therapeutics Appoints Dieter Weinand, Former CEO of Bayer Pharmaceuticals, as Independent Chairman
Ghent, Belgium – August 29, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced the appointment of Dieter Weinand as Independent Chairman of its Board of Directors. Mr. Weinand brings with him a wealth of experience with more than 35 years in the pharmaceutical industry and […]
Read Post
Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera
• Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled antibody discovery technologies on two GPCR targets • Confo to receive upfront and milestone payments • Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – June 15, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]
Read Post
Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy
US trial with leriglitazone to commence in mid-2023 providing an FDA-approved route to US market whilst EMA evaluates European Marketing Authorization Application (MAA) Mataró, Barcelona, Spain, May 31, 2023 – Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces the US Food […]
Read Post
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
– CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile – Positive results from the study to date support preparations for a registrational trial for CTx-PDE6b in PDE6b Retinitis Pigmentosa – Regulatory approval received to expand the current study to include younger patients with earlier stages […]
Read Post
ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors
• Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Dr. Pamela […]
Read Post
Indigo Appoints Dr. Arun Venkatasubramanian as Chief Technology Officer
Arun is an award-winning engineer who brings over 15 years’ experience in leading the design and development of transformational technology within the medical, consumer, and military sectors BELGIUM – Ghent, 15 May 2023 – Indigo Diabetes N.V. (‘Indigo’ or the ‘Company’), a pioneering developer of a Continuous Metabolite Monitoring (CMM™) device for people living with […]
Read Post
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)
Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment Mataró, Barcelona, Spain, April 25, 2023 – Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces 24-week interim […]
Read Post
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
Companies join forces bringing together Bristol Myers Squibb’s (BMS) deep oncology and clinical development expertise and Tubulis’ differentiated and unique approach to Antibody-Drug- Conjugate (ADC) design with the goal of delivering the true therapeutic potential of ADCs Tubulis to receive upfront payment of $22.75 million and milestone payments potentially totaling over $1 billion plus tiered […]
Read Post
Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases
Collaboration to make use of Confo’s unique suite of ConfoBody®-enabled technologies for fragment- and structure-based drug design Confo to receive upfront and milestone payments totaling EUR 168M Tiered royalties payable to Confo on net sales from resulting products Ghent, Belgium – March 30, 2023 – Confo Therapeutics, a leader in the discovery of medicines targeting […]
Read Post
ExeVir Bio and VIB Announce Data on a New Therapy for Prevention and Treatment for COVID-19.
ExeVir Bio and VIB-UGent’s bioRxiv pre-print reports on S2-binding camelid single-domain antibody-based drug, XVR013, that targets the Achilles’ heel in the SARS-CoV-2 viral spike Focus on protecting the millions of immuno-compromised patients, who are most vulnerable to COVID-19 Ghent, Belgium, 13 March 2023: ExeVir Bio, a biotech company developing robust single domain antibody therapies for broad […]
Read Post
Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if Lilly proceeds with a second product candidate Tiered royalties payable to Confo on net sales Confo to have a co-investment option Ghent, Belgium – March 2, 2023 – Confo Therapeutics, a leader in the discovery […]
Read Post
Cellaion SA announces a total fundraising of EUR 23 million in 2022 for its phase IIB study in Acute on Chronic Liver Failure with Truffle Capital as lead investor in the final Closing followed by Newton Biocapital, Wallonie Entreprendre and individual investors.
Mont-Saint-Guibert, Belgium, 2023/01/13. Cellaïon is a biotechnology company based in Mont-St-Guibert, active in the field of cell therapy, an area of excellence in the life sciences industry in Wallonia. Its flagship product HepaStem®, in advanced clinical development, targets severe liver diseases, and in particular Acute on Chronic Liver Failure (ACLF). ACLF is an acute hepatic […]
Read Post